Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG (CRSP) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $4.8B; returns 1 day -1.2%, 1 week +0.3%, 1 year -26.5%.

CRISPR Therapeutics AG (CRSP) is a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases using its CRISPR/Cas9 gene-editing technology. The company's lead product, CASGEVY, is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Groups CRSP belongs to

• Biotechnology
• Gene Therapy
• Healthcare
• Biopharmaceutical
• Life Sciences
• Sickle Cell Disease
• Commercial Stage Biotech
• Clinical Stage Biopharma
• Precision Medicine
• Hematology
• Oncology
• Autoimmune Diseases
• Rare Diseases

CRSP financial model: income statement, cash flow and balance sheet